To study the serum C-reactive protein level and its correlation with prognostic variables in stable COPD patients
Abstract
Introduction: C-reactive protein is a stable and excellent biomarker of systemic inflammation which is easy to measure. COPD is an inflammatory disorder of lung with widespread Systemic manifestations and associated Systemic inflammatory response. C-reactive protein levels are increased in COPD patients. Present study investigated C-reactive protein level in stable COPD patients and its relation with clinically important outcome variable, exercise capacity.
Method: Study included 56 stable COPD patients with mild to moderate severity in age group 40-70 years and 56 nonsmoking controls in the same age group. Clinical and physiological characteristics were determined and C-reactive protein levels were measured.
Result: This study confirms the finding of higher C-reactive protein levels in smoker COPD patients (4.9 vs 4.0 mg-L-1) as compared to nonsmoker COPD patients. It also confirms that level of C-reactive protein in ex-smoker COPD population remains significantly higher than nonsmoker control group (4.9±0.5 vs 3.1mg/l).
Conclusion: C-reactive protein level was strongly associated and correlated with 6 minute walk distance, FEV1 and GOLD stages, so C-reactive protein level can indirectly reflect prognosis of COPD patient and his exercise capacity. We recommend that measurement of C-reactive protein levels may be a useful tool to predict the prognosis and patient outcome in COPD patients. It also provides strong argument to develop therapies aimed at decreasing inflammation independent of smoking cessation.
Downloads
References
2. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003 Feb;21(2):347-60. [PubMed]
3. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1055-60. [PubMed]
4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic reviewand a meta-analysis. Thorax. 2004 Jul;59(7):574-80. [PubMed]
5. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006 Aug;130(2):326-33. [PubMed]
6. Global strategy for the diagnosis, management and prevention of COPD 2014: Diagnosis and assessment, chapter 3:14.
7. Price CP, Trull AK, Berry D, Gorman EG. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J Immunol Methods. 1987 May 20;99(2):205-11.
8. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 Mar 15;171(6):591-7. Epub 2004 Dec 10.
9. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease Eur J Intern Med. 2008 Mar;19(2):104-8. doi: 10.1016/j.ejim.2007.04.026. [PubMed]
10. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003 Oct;22(4):672-88. [PubMed]
11. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.
12. Koechlin C, Couillard A, Cristol JP, Chanez P, Hayot M, Le Gallais D, Préfaut C. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? Eur Respir J. 2004 Apr;23(4):538-44.
13. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2007 Aug;16(4):236-40.
14. Aronson D, Roterman I, Yigla M, Kerner A, Avizohar O, Sella R, Bartha P, Levy Y, Markiewicz W. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med. 2006 Sep 15;174(6):626-32. Epub 2006 Jun 15. [PubMed]
15. Gan WQ1 Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005 Feb;127(2):558-64. [PubMed]
16. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003 Mar 25;107(11):1514-9. [PubMed]
17. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2004 Oct 1;170(7):760-5. Epub 2004 Jun 30. [PubMed]
18. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006 Jan;61(1):23-8. Epub 2005 Sep 2. [PubMed]
19. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD.Thorax. 2006 Jan;61(1):17-22. Epub 2005 Jul 29.
OAI - Open Archives Initiative
